Emcure Pharmaceuticals Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Emcure Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 22 May 2025, inter alia, have recommended the final dividend of Rs 3 per equity Share (i.e. 30%) , subject to the approval of the shareholders.

Powered by Capital Market - Live News

Net profit of Emcure Pharmaceuticals rose 64.07% to Rs 188.96 crore in the quarter ended March 2025 as against Rs 115.17 crore during the previous quarter ended March 2024. Sales rose 19.47% to Rs 2116.25 crore in the quarter ended March 2025 as against Rs 1771.36 crore during the previous quarter ended March 2024.

For the full year,net profit rose 36.76% to Rs 681.33 crore in the year ended March 2025 as against Rs 498.18 crore during the previous year ended March 2024. Sales rose 18.59% to Rs 7896.00 crore in the year ended March 2025 as against Rs 6658.25 crore during the previous year ended March 2024.

Powered by Capital Market - Live News

Emcure Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 22 May 2025.

Powered by Capital Market - Live News

The company received the Establishment Inspection Report (EIR) from the USFDA following an inspection conducted between 19 February 2025 and 25 February 2025. According to an exchange filing dated 26 February 2025, the inspection concluded with the issuance of two observations in Form 483.

Pune-based Emcure Pharmaceuticals is a leading Indian pharma company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products.

The company?s consolidated net profit surged 35.5% to Rs 153.72 crore in Q3 FY25 as against Rs 113.45 crore posted in Q3 FY24. Revenue from operations jumped 17.7% YoY to Rs 1,962.63 crore in the quarter ended 31 December 2024.

The scrip shed 0.89% to Rs 1,084.95 on the BSE.

Powered by Capital Market - Live News